{"id":"d-1553","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hyperglycemia"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL577437","moleculeType":"Small molecule","molecularWeight":"543.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"D-1553 works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of AKT and mTOR, resulting in anti-tumor effects.","oneSentence":"D-1553 is a small molecule that targets the PI3K/AKT/mTOR pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:19.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors with PI3K pathway alterations"}]},"trialDetails":[{"nctId":"NCT06166836","phase":"PHASE1, PHASE2","title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-10-12","conditions":"Solid Tumor","enrollment":140},{"nctId":"NCT07174908","phase":"PHASE3","title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2025-09-10","conditions":"Non-Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07318649","phase":"PHASE2","title":"Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Genhouse Bio Co., Ltd.","startDate":"2025-12-30","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":120},{"nctId":"NCT05379946","phase":"PHASE1, PHASE2","title":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2022-10-12","conditions":"Solid Tumor","enrollment":92},{"nctId":"NCT04585035","phase":"PHASE1, PHASE2","title":"Study to Evaluate D-1553 in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2020-10-02","conditions":"Solid Tumor, Adult, NSCLC, CRC","enrollment":180},{"nctId":"NCT05492045","phase":"PHASE1, PHASE2","title":"A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"InventisBio Co., Ltd","startDate":"2022-09-13","conditions":"NSCLC","enrollment":22},{"nctId":"NCT05383898","phase":"PHASE1, PHASE2","title":"Study to Evaluate D-1553 in Subjects With Lung Cancer","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2021-03-16","conditions":"NSCLC","enrollment":225},{"nctId":"NCT06105255","phase":"PHASE1","title":"A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2023-05-24","conditions":"Healthy Male","enrollment":45},{"nctId":"NCT06435455","phase":"PHASE1, PHASE2","title":"GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Genhouse Bio Co., Ltd.","startDate":"2024-07-01","conditions":"Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation","enrollment":126},{"nctId":"NCT06300177","phase":"PHASE3","title":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-03-28","conditions":"Non Small Cell Lung Cancer","enrollment":522},{"nctId":"NCT06233916","phase":"PHASE1","title":"Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2023-12-08","conditions":"Mass Balance Study","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["other"],"phase":"phase_3","status":"active","brandName":"D-1553","genericName":"D-1553","companyName":"InventisBio Co., Ltd","companyId":"inventisbio-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D-1553 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Advanced solid tumors with PI3K pathway alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}